Paul Eckburg serves as Executive at AN2 Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Paul Eckburg has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Mar 15, 2024 involved receiving (via award) 30,000 shares valued at $0.
Paul Eckburg currently holds 51,416 shares of AN2 Therapeutics, Inc. (ANTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Paul Eckburg has been a net neutral trader of ANTX stock. They have purchased $0 and sold $0 worth of shares.
Paul Eckburg's most recent insider trade was on Mar 15, 2024, when they sold 30,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |